Journal Article Review Ppublish 101 citations
PubMed: 36073299 DOI: 10.1111/jpc.16197
Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions.
J Paediatr Child Health 58(10):1741-1746
Authors: Elly Binns, Jane Tuckerman, Paul V Licciardi, Danielle Wurzel
Affiliations
- Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia.
- The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
- School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
- Department of Respiratory Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia.
Abstract
Globally, respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and pneumonia in young children, and the association between severe RSV disease and later recurrent wheeze and asthma is well established. Whilst a causal link between RSV and wheeze/asthma is not yet proven, immunological evidence suggests skewing towards a Th2-type response, and dampening of IFN-γ antiviral immunity during RSV infection underpins airway hyper-reactivity in a subset of susceptible children after RSV infection. Age at primary RSV infection, viral co-infection and genetic influences may act as effect-modifiers. Despite the significant morbidity and mortality burden of RSV disease in children, there is currently no licensed vaccine. Recent advancements in RSV preventatives, including long-acting monoclonal antibodies and maternal vaccinations, show significant promise and we are on the cusp of a new era in RSV prevention. However, the potential impact of RSV preventatives on subsequent wheeze and asthma remains unclear. The ongoing COVID-19 pandemic and associated public health measures have disrupted the usual seasonality of RSV. Whilst this has posed challenges for health-care services it has also enhanced our understanding of RSV transmission. The near absence of RSV cases during the first year of the pandemic in the context of strict public health measures has provided a rare opportunity to study the impact of delayed age of primary RSV infection on asthma prevalence. In this review, we summarise current understanding of the association between RSV, recurrent wheeze and asthma with a focus on pathophysiology, preventative strategies and future research priorities.
MeSH
Respiratory Syncytial Viruses, Child Welfare, Public Health, Infant Welfare, Viruses, Pandemics, Pediatrics, Asthma, Palivizumab, Infections, Child, Respiratory Syncytial Virus Infections
Cited by
- Innate Lymphoid Cells and Their Role in the Immune Response to Infections. Cells, 2024
- Pyroptosis in asthma: inflammatory phenotypes, immune and non-immune cells, and novel treatment approaches. Front Pharmacol, 2024
- Universal administration of nirsevimab in infants: an analysis of hospitalisations and paediatric intensive care unit admissions for RSV-associated lower respiratory tract infections. Eur J Pediatr, 2025
- Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens, 2023
- Clinical and public health measures to cope with respiratory syncytial virus infection. Asian Biomed (Res Rev News), 2025
- Respiratory Syncytial Virus: A Narrative Review of Updates and Recent Advances in Epidemiology, Pathogenesis, Diagnosis, Management and Prevention. J Clin Med, 2025
- Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants. Hum Vaccin Immunother, 2025
- Cost of respiratory syncytial virus hospitalisation in Brazilian infants: a micro-costing study from the perspective of a Brazilian tertiary public hospital, 2020-2023. BMC Public Health, 2025
- New Insights on Respiratory Syncytial Virus Prevention. Vaccines (Basel), 2023
- Respiratory syncytial virus: A review of current basic and clinical knowledge. Qatar Med J, 2025
- Respiratory Syncytial Virus Infection: Treatments and Clinical Management. Vaccines (Basel), 2023
- RSV Disease Burden in Primary Care in Italy: A Multi-Region Pediatric Study, Winter Season 2022-2023. Influenza Other Respir Viruses, 2024
- Infants born during COVID-19 pandemic experience increased susceptibility to airway hyperresponsiveness. Front Allergy, 2024
- Lung-resident lymphocytes and their roles in respiratory infections and chronic respiratory diseases. Chin Med J Pulm Crit Care Med, 2025
- Clinical Predictors of Severe Exacerbations in Pediatric Patients With Recurrent Wheezing. Cureus, 2024
- Exploring the Contribution of TLR7 to Sex-Based Disparities in Respiratory Syncytial Virus (RSV)-Induced Inflammation and Immunity. Viruses, 2025
- The dysfunction of Tfh cells promotes pediatric recurrent respiratory tract infections development by interfering humoral immune responses. Heliyon, 2023
- Inactivated Mycobacterial Vaccine Nebulized Inhalation: A Effective Therapy for the Prevention and Treatment of Respiratory Diseases? Clin Respir J, 2025
- Biological activity analysis of baicalin nanodrugs: Nanosizing enhances antiviral and anti-inflammatory effects in the treatment of viral pneumonia. J Pharm Anal, 2025